Abstract A142: Circulating tumor DNA as a prognostic biomarker in PDAC: Insights from Real-World Data
Pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis with few validated biomarkers for disease monitoring. Circulating tumor DNA (ctDNA) is a promising liquid biopsy-based biomarker, but its clinical utility remains incompletely defined. While most available data focus on early-stage disease, we eva...